This clinical trial is focused on studying the effects of a medication called Guselkumab in individuals with Moderately to Severely Active Ulcerative Colitis. Ulcerative colitis is a chronic condition that causes inflammation and sores in the lining of the large intestine, leading to symptoms like abdominal pain and diarrhea. The medication being tested, Guselkumab, is a type of treatment known as a monoclonal antibody, which is administered through an injection or infusion. It is designed to target specific proteins in the body to help reduce inflammation.

The purpose of this study is to evaluate how effective and safe Guselkumab is for people with this condition. Participants in the study will receive either Guselkumab or a placebo, which is a substance with no active medication. The study will follow a structured plan where participants will receive the treatment over a period of time, and their health will be monitored to assess the medication’s impact on their ulcerative colitis symptoms.

Throughout the study, participants will undergo regular check-ups to track their progress and any changes in their condition. The goal is to determine if Guselkumab can provide relief from the symptoms of ulcerative colitis and improve the quality of life for those affected by this disease. The study is designed to ensure the safety and well-being of all participants while gathering important information about the potential benefits of this treatment.